Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy

Ando, Takayuki; Hosokawa, Ayumu; Kajiura, Shinya; Itaya, Yuko; Ueda, Akira; Fujinami, Haruka; Nishikawa, Jun; Kobayashi, Takashi; Horikawa, Naoki; Tsukioka, Yuji; Yabushita, Kazuhisa; Ogawa, Kohei; Sugiyama, Toshiro

doi:10.1007/s10120-011-0135-0

Cited by 20 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is a clinical study showing that paclitaxel may help alleviate ERCC1-related platinum resistance in ovarian cancer [39]. Cisplatin monotherapy is not commonly used; taxane monotherapy is used to treat advanced gastric cancer [40,41]. Thus, paclitaxel might play a greater role than cisplatin in patients with advanced gastric cancer treated with taxane-cisplatin chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

et al. 2013

View full text Add to dashboard Cite

BackgroundClass III β-tubulin (TUBB3) is a prognostic marker in various tumors, but the role of TUBB3 in advanced gastric cancer is not clearly defined. We analyzed the significance of TUBB3 expression, along with that of excision repair cross-complementation group 1 (ERCC1) in recurrent and metastatic gastric cancer patients receiving taxane-based first-line palliative chemotherapy.MethodsWe reviewed the cases of 146 patients with advanced gastric adenocarcinoma who received taxane-based first-line palliative chemotherapy between 2004 and 2010 at Chonnam National University Hwasun Hospital (Gwangju, Korea). Immunohistochemical staining for TUBB3 and ERCC1 was performed using paraffin wax-embedded tumor tissues. We evaluated the patients’ response to chemotherapy, progression-free survival (PFS), and overall survival (OS).ResultsIn total, 146 patients with advanced gastric cancer received docetaxel and cisplatin (n = 15) or paclitaxel and cisplatin (n = 131). The median PFS was significantly shorter for patients with high-level TUBB3 expression than for patients with low-level TUBB3 expression (3.63 vs. 6.67 months, P = 0.001). OS was not associated with TUBB3 expression (13.1 vs. 13.1 months, P = 0.769). By multivariate analysis, only TUBB3 was related to a shorter PFS (HR 2.74, 95% CI 1.91-3.91, P = 0.001). Patients with high-level ERCC1 expression showed a lower response rate than patients with low-level ERCC1 expression (24 vs. 63.2%, P = 0.001); however, ERCC1 had no clinical effect on PFS or OS.ConclusionsTUBB3 was a strong predictive marker in recurrent and metastatic gastric cancer patients receiving taxane-based first-line palliative chemotherapy. No clinical impact of ERCC1 was evident in this setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…However, complete cross-resistance between PTX and DTX was observed in MCF-7 cells [22], indicating varying degrees of cross-resistance between cancer types. Several clinical analyses also show incomplete cross-resistance between PTX and DTX in breast [23,24], ovarian [25] and gastric cancer [15] patients. Hence, incomplete cross-resistance between PTX and DTX was expected in the present esophageal cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…However, incomplete cross-resistance between these drugs has been indicated in several in vitro and in vivo studies of various cancer types [11,13,14,15]. Accordingly, we assumed incomplete cross-resistance between PTX and DTX in patients with esophageal squamous cell carcinoma, and performed a retrospective study to assess the efficacy and safety of sequential treatments with taxanes in patients with esophageal squamous cell carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

et al. 2016

View full text Add to dashboard Cite

Background: Incomplete cross-resistances between paclitaxel (PTX) and docetaxel (DTX) has been demonstrated in several types of cancer. The objective of the present study was to assess the existence of cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Methods: Patients in the PTX group received PTX without DTX pretreatment, patients in the prior DTX (Pr-DTX) group received PTX after the development of resistance to DTX, and patients in the DTX group received DTX without subsequent PTX treatment. Results: A total of 73 patients were enrolled. The response rates to PTX in the PTX and Pr-DTX groups were 22.7 and 20.0%, respectively. The median progression-free survival times from the first day of PTX treatment in the PTX and Pr-DTX groups were 113 (95% CI 56-154) and 97 days (95% CI 36-189), respectively. The median overall survival times from the first day of DTX treatment in the Pr-DTX and DTX groups were 315 (95% CI 124-453) and 148 days (95% CI 139-177), respectively. Conclusions: There is no or incomplete clinical cross-resistance between PTX and DTX in esophageal squamous cell carcinoma. Replacement of DTX with PTX is a suitable treatment option for patients with DTX-resistant esophageal squamous cell carcinoma.

show abstract

“…In another phase II trial incorporating PTX with S-1, Wang et al [8] reported an overall response rate of 46.3 %. When used as a single agent in patients with docetaxel-refractory advanced GC, PTX also showed certain therapeutic benefit [9,10]. Lately, even more promising results came from a phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer, which showed an overall response rate of 27.8 % and disease control rate of 59.3 % [11].…”

Section: Introductionmentioning

confidence: 99%

Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel

Jin

Liu

Wang

2015

Cell Biochem Biophys

View full text Add to dashboard Cite

The development of drug resistance has largely limited the clinical outcome of anti-cancer treatment. Recent work has highlighted the involvement of non-coding RNAs, microRNAs (miRNAs), in cancer development. The present study aimed to investigate the role of miR-21 in the development of drug resistance to paclitaxel in gastric cancer cells. Our study found that the expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901. Moreover, over-expression of miR-21 significantly decreased antiproliferative effects and apoptosis induced by paclitaxel, while knockdown of miR-21 dramatically increased antiproliferative effects and apoptosis induction by paclitaxel. Moreover, our results demonstrated that miR-21 may modulate the sensitivity to PTX, at least in part, by regulating the expression of P-glycoprotein.

show abstract

Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy

Abstract: Weekly paclitaxel was modestly active in patients with gastric cancer refractory to docetaxel-based chemotherapy.

Cited by 20 publications

References 25 publications

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer

Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma

Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel

Contact Info

Product

Resources

About